The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Gilead Appoints Dr. Muzammil M. Mansuri as Senior Vice President, Research and Development Strategy and Corporate Development

Wednesday, April 27, 2011

Gilead Appoints Dr. Muzammil M. Mansuri as Senior Vice President, Research and Development Strategy and Corporate Development16:05 EDT Wednesday, April 27, 2011 FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today the appointment of Muzammil M. (“Muz”) Mansuri, PhD, to Senior Vice President, Research and Development Strategy and Corporate Development, a role that expands his current responsibilities as Senior Vice President, Research and Development Strategy to include leadership of Corporate Development and Alliance Management. In this new role, Dr. Mansuri will help to define and implement Gilead's research and development strategy, explore new business opportunities, drive strategic and portfolio management activities, and build and manage Gilead's alliances, partnerships and acquisitions. Dr. Mansuri will report both to John F. Milligan, PhD, Gilead's President and Chief Operating Officer, and to Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Mansuri joined Gilead in July 2010, following the company's acquisition of CGI Pharmaceuticals, Inc. Prior to joining Gilead, Dr. Mansuri served as the Chief Executive Officer or Chief Operating Officer at several small biotechnology companies, including CGI, BIKAM Pharmaceuticals, Sequoia Pharmaceuticals, GPC Biotech and Mitotix, Inc. He also was a general partner with Flagship Ventures and served on the boards of CGI, AVEO Pharmaceuticals, BG Medicine and Adaptive Therapeutics. Earlier in his career, Dr. Mansuri spent 10 years with Bristol-Myers Squibb, where he initiated antiretroviral chemistry efforts for d4T and led the project team that developed the compound for the treatment of HIV. “Since joining Gilead, Muz has played a key role in efforts to expand our pipeline into the areas of oncology and inflammation with the acquisitions of Arresto Biosciences and Calistoga Pharmaceuticals,” said Dr. Milligan. “His broad knowledge of research and clinical development will be instrumental as we evaluate opportunities to partner with other companies and institutions to advance novel therapies in areas of significant unmet need.” Dr. Mansuri received his bachelor of science and doctoral degrees from University College London, University of London, and completed post-doctoral fellowships at Columbia University and the University of California, Los Angeles. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). Gilead Sciences, Inc.Patrick O?Brien, 650-522-1936 (Investors)Nathan Kaiser, 650-522-1853 (Media)